regulatory
confidence high
sentiment positive
materiality 0.75
Century Therapeutics regains Nasdaq bid price compliance; reverse split not needed
Century Therapeutics, Inc.
- Nasdaq notified Century on Jan 22, 2026 that it regained compliance with minimum $1.00 bid price rule.
- Stockholders approved reverse stock split (1:5–1:30) at special meeting earlier that day.
- Company will not implement the reverse split due to regained compliance.
- No other business was conducted; adjournment proposal was unnecessary.